Dianthus Therapeutics, Inc. /DE/ DNTH

About Dianthus Therapeutics, Inc. /DE/ (DNTH): stock profile, AI score and financials

Dianthus Therapeutics, Inc. /DE/ (DNTH) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DNTH at 25.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,613 of 2,925 stocks — the bottom half of the AI-ranked universe. DNTH scores in the top quartile across revenue growth (97.0). Areas of concern include free cash flow (1.9) and profitability (2.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Dianthus Therapeutics, Inc. /DE/ reports quarterly revenue of $11.5M, net income of $-50.2M, free cash flow of $-49.2M. Top institutional holders of DNTH by reported 13-F value include FMR, BlackRock, T. Rowe Price Investment Management, based on the most recent SEC filings. DNTH trades on the Nasdaq exchange and files with the SEC under CIK 1690585. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DNTH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Dianthus Therapeutics, Inc. /DE/ directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1690585 →